Revelation Biosciences Inc

NASDAQ:REVBUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).

Contact Information

Headquarters

4660 Lajolla Village Drive, Suite 100SAN DIEGO, CA, United States 92122

Phone

650-800-3717

Fax

302-645-1280

Executives

Independent Chairman of the Board

George Tidmarsh

Chief Executive Officer, Co-Founder, Director

James Rolke

Chief Financial Officer

Chester Zygmont

Independent Director

Jennifer Carver

Independent Director

Lakhmir Chawla